



## Javelin Pharmaceuticals CEO Martin J. Driscoll to Present at J.P. Morgan's 27th Annual Healthcare Conference

CAMBRIDGE, Mass., Jan 08, 2009 (BUSINESS WIRE) --

Javelin Pharmaceuticals (NYSE Alternext US: JAV) announced today that Martin J. Driscoll, CEO will present at J.P. Morgan's 27th Annual Healthcare Conference at 11:30 a.m. PT on Thursday, January 15, 2009 at the Westin St. Francis Hotel in San Francisco, CA. Mr. Driscoll will provide a company overview and update on the status of Javelin's clinical and commercialization activities.

Javelin's presentation will be webcast live from both Javelin's website, [www.javelinpharma.com](http://www.javelinpharma.com) and J.P. Morgan's Events website - <http://events.jpmorgan.com> and will remain available for replay until April 15, 2009.

About Javelin Pharmaceuticals, Inc.:

With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has one marketed drug in the UK and three drug candidates in US Phase 3 clinical development. For additional information about Javelin, please visit the Company's website at <http://www.javelinpharmaceuticals.com>.

Forward Looking Statement:

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials and their outcome, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies and other risks described in our annual and quarterly reports filed with the Securities and Exchange Commission.

JAV-G

SOURCE: Javelin Pharmaceuticals, Inc.

Investor Contacts:

Javelin Pharmaceuticals, Inc.

Rick Pierce, 617-349-4500

VP Investor Relations

[rpierce@javelinpharma.com](mailto:rpierce@javelinpharma.com)

or

June Gregg, Manager Corporate Communications

[jgregg@javelinpharma.com](mailto:jgregg@javelinpharma.com)

Copyright Business Wire 2009

News Provided by COMTEX